EP1178809A1 - Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel - Google Patents
Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrelInfo
- Publication number
- EP1178809A1 EP1178809A1 EP00922737A EP00922737A EP1178809A1 EP 1178809 A1 EP1178809 A1 EP 1178809A1 EP 00922737 A EP00922737 A EP 00922737A EP 00922737 A EP00922737 A EP 00922737A EP 1178809 A1 EP1178809 A1 EP 1178809A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- acetylsalicylic acid
- clopidogrel
- hydrogen sulfate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- composition in unit form containing acetylsalicylic acid and clopidogrel hydrogen sulfate
- the present invention relates to a pharmaceutical composition in a unit dosage form containing an association of active principles with antiplatelet activity consisting of acetylsalicylic acid, also known under the brand name Aspirin, and clopidogrel hydrogen sulfate.
- the unit dosage form can be administered orally and preferably consists of a tablet, a capsule or a dose sachet.
- acetylsalicylic acid is used in its acid form and clopidogrel hydrogen sulphate can be used in the form of one or other of its polymorphs known to date and called Form 1 (F1) or Form 2 (F2).
- Form 1 is the salt described in patent EP 281459 and clopidogrel hydrogen sulfate Form 2 is that described in patent application FR 98 07464.
- the therapeutic advantage of the combination of acetylsalicylic acid and of clopidogrel is among others described in patent application WO 97/29753.
- compositions are mentioned there without ever specifying that the pharmaceutically acceptable salt used is clopidogrel hydrogen sulfate. This document always indicates that the composition can be used parenterally or orally and that it is possible to administer the active ingredients according to four modes of administration, namely, both orally, both parenterally or one orally and the other parenterally or vice versa.
- the tablets according to the invention can be obtained by various manufacturing processes such as for example:
- the direct compression process in which the active ingredients and the selected excipients are mixed.
- the mixture obtained is sieved (calibrated) on a previously defined mesh opening grid, in order to homogenize the particle sizes of the constituents.
- a new mixing is carried out to ensure good homogeneity of the active ingredients.
- Specific excipients (example: a flow agent) as well as a lubricant are added and mixed.
- the final mixture obtained is then compressed.
- Dry granulation consists in ensuring that the active ingredients and the selected excipients are mixed, calibrated and then mixed again.
- the mixture is forced between two mobile cylinders, in opposite directions of rotation, in order to obtain, according to the forces exerted, plates of determined mechanical strengths. These plates are calibrated.
- the specific excipients are added and the final mixture compressed.
- Hot melt granulation is a granulation process that can be used when an active ingredient degrades in the presence of water.
- the active ingredients and the selected excipients are calibrated and then mixed.
- the mixture is brought under slow stirring to a temperature slightly higher than that of the melting point of the excipient, mixed under rapid stirring, then cooled to room temperature.
- the grain obtained is calibrated.
- the specific excipients are added and the final mixture compressed.
- An example of a "hot melt” process in a granulator with a fluidized air bed is described below.
- the active ingredients and the selected excipients, except the fusible excipient are calibrated and then transferred to a granulator with a fluidized air bed.
- the whole is mixed by fluidization with supply of hot air, up to a temperature of the mixture slightly lower than that of the melting point of the granulation excipient.
- the molten excipient is then sprayed onto the fluidized mixture.
- the temperature of the fluidizing air is lowered.
- the grain obtained is calibrated.
- the specific excipients are added and the final mixture compressed.
- the capsules and dose sachets are prepared according to techniques well known to those skilled in the art.
- the pharmaceutical compositions according to the invention are used for the treatment of a pathology induced by platelet aggregation including stable or unstable angina, disorders of the cardiovascular and cerebrovascular system such as thromboembolic disorders associated with atherosclerosis and diabetes such as unstable angina, cerebral attack, restenosis after angioplasty, endarterectomy or fitting of metal endovascular prostheses or thromboembolic disorders associated with rethrombosis after thrombolysis, infarction, dementia of ischemic origin, peripheral arterial diseases, hemodialysis, atrial fibrillation or even when using vascular prostheses, bypass surgery, or during radiotherapy to reduce side effects.
- compositions according to the invention are used for the preparation of a medicament intended for the treatment of the pathologies mentioned above and allow the treatment of these pathologies.
- clopidogrel hydrogen sulfate and acetylsalicylic acid are present in a molar ratio of clopidogrel hydrogenosulfate / acetylsalicylic acid comprised between 2.5 and 11, preferably between 5 and 9.
- clopidogrel hydrogen sulfate 1 to 500 mg per day of clopidogrel hydrogen sulfate and 1 to 500 mg per day of acetylsalicylic acid are administered to humans, the doses being expressed in equivalent amounts of clopidogrel in free form.
- clopidogrel hydrogen sulfate is administered and 75 to
- compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 75 mg of acetylsalicylic acid are particularly preferred.
- compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid Preference is also given to compositions containing 97.875 mg of clopidogrel hydrogen sulfate and 375 mg of acetylsalicylic acid.
- Example granulation process by compacting
- Anhydrous lactose ⁇ can be replaced in an equivalent amount with mannitol.
- Example granulation process by compacting
- Mannitol can be replaced in an equivalent amount by anhydrous lactose ⁇ .
- a) 97.875 g of clopidogrel hydrogenosulfate are mixed with 2 g of anhydrous colloidal silica b) 325 g of acetylsalicylic acid, 30 g of corn starch, 124.6 g of mannitol and 60 g of microcrystalline cellulose are added to a) and mixed c)
- the mixture b) is calibrated and then mixed again d) 10.5 g of hydrogenated castor oil are added to c) before the final mixture e)
- the final mixture is compressed to a theoretical unit mass of 650 mg
- the mixture is made in mini-rhôn for 10 minutes between the active ingredients and the diluents.
- the active ingredients are mixed with the mini-rhôn for 10 minutes with the diluents.
- Anhydrous colloidal silica is added to the above mixture and then sieved through a grid of 0.315 mm mesh opening.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9905497 | 1999-04-30 | ||
FR9905497A FR2792836B3 (fr) | 1999-04-30 | 1999-04-30 | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
PCT/FR2000/001086 WO2000066130A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1178809A1 true EP1178809A1 (fr) | 2002-02-13 |
Family
ID=9545071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00922737A Withdrawn EP1178809A1 (fr) | 1999-04-30 | 2000-04-25 | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1178809A1 (es) |
JP (1) | JP2002543137A (es) |
KR (1) | KR20020005735A (es) |
CN (1) | CN1359294A (es) |
AR (1) | AR023789A1 (es) |
AU (1) | AU4303600A (es) |
BR (1) | BR0010194A (es) |
CA (1) | CA2371231A1 (es) |
CZ (1) | CZ20013887A3 (es) |
EA (1) | EA200100959A1 (es) |
EE (1) | EE200100559A (es) |
FR (1) | FR2792836B3 (es) |
HK (1) | HK1041823A1 (es) |
HU (1) | HUP0202329A2 (es) |
IL (1) | IL145648A0 (es) |
IS (1) | IS6084A (es) |
MX (1) | MXPA01011071A (es) |
NO (1) | NO20015295L (es) |
NZ (1) | NZ514248A (es) |
PL (1) | PL351923A1 (es) |
SK (1) | SK15542001A3 (es) |
TR (1) | TR200103039T2 (es) |
UY (1) | UY26131A1 (es) |
WO (1) | WO2000066130A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2432644C (en) | 2000-12-25 | 2013-07-23 | Fumitoshi Asai | Pharmaceutical composition comprising aspirintm and cs-747 |
US6767913B2 (en) | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
JP4917255B2 (ja) * | 2003-10-16 | 2012-04-18 | 第一三共ヘルスケア株式会社 | サリチル酸類含有経口組成物 |
WO2005070464A2 (en) * | 2004-01-21 | 2005-08-04 | Biofarma Ilac Sanayi Ve Ticaret A.S. | A tablet formulation of clopidogrel bisulphate |
US20070003615A1 (en) * | 2005-06-13 | 2007-01-04 | Elan Pharma International Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
KR20070009851A (ko) * | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
KR100736024B1 (ko) * | 2005-09-21 | 2007-07-06 | 주식회사종근당 | 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 |
KR20070044323A (ko) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 |
US20100145053A1 (en) * | 2006-04-05 | 2010-06-10 | Cadila Healthcare Limited | Modified release clopidogrel formulation |
EP1900358A1 (en) * | 2006-09-16 | 2008-03-19 | Cimex Pharma AG | Pharmaceutical formulations comprising clopidogrel |
HUP0600839A3 (en) * | 2006-11-14 | 2008-09-29 | Egis Gyogyszergyar Nyrt | Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof |
CN101951896B (zh) * | 2008-02-22 | 2012-11-28 | 韩兀生物制药株式会社 | 复合制剂 |
CN101695496A (zh) * | 2009-10-15 | 2010-04-21 | 苏春华 | 一种含有三氟柳和氯吡格雷的药物组合物 |
JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
RU2484820C2 (ru) * | 2011-02-24 | 2013-06-20 | Общество с ограниченной ответственностью "Озон" | Комбинированное лекарственное средство, являющееся ингибитором агрегации тромбоцитов |
KR101675501B1 (ko) * | 2011-11-02 | 2016-11-14 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
JP6004524B2 (ja) * | 2012-07-11 | 2016-10-12 | 大原薬品工業株式会社 | クロピドグレル硫酸塩含有錠剤の製造方法 |
WO2015015062A1 (fr) * | 2013-08-02 | 2015-02-05 | Sanofi | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
CN104434932B (zh) * | 2014-12-18 | 2017-05-24 | 成都苑东生物制药股份有限公司 | 一种硫酸氢氯吡格雷阿司匹林片药物组合物及其制备方法 |
WO2017037741A1 (en) * | 2015-09-02 | 2017-03-09 | Sun Pharmaceutical Industries Ltd | Compact solid dosage form of aspirin and clopidogrel |
CN115737578A (zh) * | 2022-11-23 | 2023-03-07 | 石家庄四药有限公司 | 一种硫酸氢氯吡格雷阿司匹林复方片及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
US5576328A (en) * | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
FR2744918B1 (fr) | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
-
1999
- 1999-04-30 FR FR9905497A patent/FR2792836B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-25 PL PL00351923A patent/PL351923A1/xx not_active Application Discontinuation
- 2000-04-25 CN CN00807001A patent/CN1359294A/zh active Pending
- 2000-04-25 WO PCT/FR2000/001086 patent/WO2000066130A1/fr not_active Application Discontinuation
- 2000-04-25 KR KR1020017013830A patent/KR20020005735A/ko not_active Application Discontinuation
- 2000-04-25 EP EP00922737A patent/EP1178809A1/fr not_active Withdrawn
- 2000-04-25 HU HU0202329A patent/HUP0202329A2/hu unknown
- 2000-04-25 BR BR0010194-0A patent/BR0010194A/pt not_active Application Discontinuation
- 2000-04-25 SK SK1554-2001A patent/SK15542001A3/sk unknown
- 2000-04-25 EE EEP200100559A patent/EE200100559A/xx unknown
- 2000-04-25 TR TR2001/03039T patent/TR200103039T2/xx unknown
- 2000-04-25 CA CA002371231A patent/CA2371231A1/en not_active Abandoned
- 2000-04-25 IL IL14564800A patent/IL145648A0/xx unknown
- 2000-04-25 CZ CZ20013887A patent/CZ20013887A3/cs unknown
- 2000-04-25 JP JP2000615014A patent/JP2002543137A/ja not_active Withdrawn
- 2000-04-25 NZ NZ514248A patent/NZ514248A/xx unknown
- 2000-04-25 AU AU43036/00A patent/AU4303600A/en not_active Abandoned
- 2000-04-25 EA EA200100959A patent/EA200100959A1/ru unknown
- 2000-04-25 MX MXPA01011071A patent/MXPA01011071A/es unknown
- 2000-04-28 UY UY26131A patent/UY26131A1/es not_active Application Discontinuation
- 2000-04-28 AR ARP000102020A patent/AR023789A1/es unknown
-
2001
- 2001-09-25 IS IS6084A patent/IS6084A/is unknown
- 2001-10-29 NO NO20015295A patent/NO20015295L/no not_active Application Discontinuation
-
2002
- 2002-05-14 HK HK02103639.9A patent/HK1041823A1/zh unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0066130A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO20015295L (no) | 2001-12-21 |
AU4303600A (en) | 2000-11-17 |
PL351923A1 (en) | 2003-06-30 |
NO20015295D0 (no) | 2001-10-29 |
FR2792836B3 (fr) | 2001-07-27 |
FR2792836A1 (fr) | 2000-11-03 |
KR20020005735A (ko) | 2002-01-17 |
CN1359294A (zh) | 2002-07-17 |
HUP0202329A2 (en) | 2002-10-28 |
IS6084A (is) | 2001-09-25 |
IL145648A0 (en) | 2002-06-30 |
NZ514248A (en) | 2003-06-30 |
UY26131A1 (es) | 2000-12-29 |
WO2000066130A1 (fr) | 2000-11-09 |
SK15542001A3 (sk) | 2002-02-05 |
CA2371231A1 (en) | 2000-11-09 |
MXPA01011071A (es) | 2002-07-22 |
AR023789A1 (es) | 2002-09-04 |
JP2002543137A (ja) | 2002-12-17 |
HK1041823A1 (zh) | 2002-07-26 |
BR0010194A (pt) | 2002-02-13 |
EE200100559A (et) | 2003-02-17 |
TR200103039T2 (tr) | 2002-01-21 |
EA200100959A1 (ru) | 2002-06-27 |
CZ20013887A3 (cs) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000066130A1 (fr) | Composition pharmaceutique sous forme unitaire contenant de l'acide acetylsalicylique et de l'hydrogenosulfate de clopidogrel | |
US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
RU2240795C2 (ru) | Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления | |
EP0330532B1 (fr) | Nouvelle forme galénique du fénofibrate | |
JP2720932B2 (ja) | 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤 | |
US6180138B1 (en) | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption | |
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
FR2460667A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
RU2238087C2 (ru) | Композиции контролируемого высвобождения, содержащие нимесулид | |
PL200957B1 (pl) | Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej | |
FR2585570A1 (fr) | Procede de preparation d'une forme granulaire a liberation retardee d'un principe actif et forme granulaire obtenue | |
FR2797587A1 (fr) | Nouvelle composition pharmaceutique | |
FR2561524A1 (fr) | Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage | |
EP1108424B2 (fr) | Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale | |
EP1353663B1 (fr) | Comprimes de fenofibrate | |
JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
PL194847B1 (pl) | Sposób wytwarzania nowych fenofibratowych preparatów galenowych, otrzymane preparaty galenowe i zastosowanie ciekłego medium | |
EP2814465B1 (en) | Pharmaceutical formulation having improved stability | |
US5290569A (en) | Coated composition and its preparation process | |
CN114146089B (zh) | 含依非韦伦、替诺福韦和恩曲他滨的药物组合物 | |
FR2489146A1 (fr) | Composition pharmaceutique a liberation prolongee a base d'une substance medicamenteuse solide | |
CA2329232C (en) | Stable compositions comprising levosimendan and alginic acid | |
KR20100041780A (ko) | 옥스카르바제핀을 포함하는 방출 제어형 고체 제제의 제조 방법 및 그에 의해 얻어질 수 있는 제제 | |
EP2946771B1 (en) | Water-dispersible tablet formulation comprising deferasirox | |
JP2000516601A (ja) | 水溶性化合物及びセルロースを含有する粒状物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011130 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20011130;LT PAYMENT 20011130;LV PAYMENT 20011130;MK PAYMENT 20011130;RO PAYMENT 20011130;SI PAYMENT 20011130 |
|
17Q | First examination report despatched |
Effective date: 20020208 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030822 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1041823 Country of ref document: HK |